Mirae Asset Global ETFs Holdings’s Avalo Therapeutics AVTX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$480K	Buy	+25,712	New	+$406K	﹤0.01%	2029

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's AVTX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 25,712 shares worth $480K. The stake represents ﹤0.01% of the portfolio and ranks #2029 among its holdings.

126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 25,712 shares of Avalo Therapeutics worth $480K as of Q2 2026.
Avalo Therapeutics was a new Mirae Asset Global ETFs Holdings position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2029 holding.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.